Kornimate/medical-research-clean huggingface dataset:
expectation and satisfaction of implant rehab after jaw surgery

Conditions: Missing Teeth

Summary: objective: the aim of this prospective study was to investigate the patient-reported outcome measures (proms) of implant-supported prostheses (isp) among patients who had excised pathological jaw lesions. material and methods: patients who met the inclusion/exclusion criteria in a dental teaching hospital were recruited. data pertaining to sociodemographic factors, conditions requiring surgery, surgical procedures and related complications, and types of isp were collected. patients' expectation and satisfaction to the isp including oral health, self-perceived appearance, speech, chewing ability, oral comfort and ease of cleaning were assessed using the visual analogue scale (vas, 0-100) and global transitional scale/judgement (likert scale). data were analysed using t-test and chi-square tests at the significance level α=0.05.


Eligibility criteria:
inclusion criteria: * subjects who have received surgical removal of pathological jaw lesions in queen mary hospital * subjects who plan to receive implant-supported prostheses in prince philip dental hospital exclusion criteria: * subjects with debilitating illnesses or complicating medical conditions * subjects who under age of 18 or unable to give consent * subjects with uncontrolled caries and periodontal disease

Keywords: dental implants oral surgical procedures dental prosthesis, implant-supported patient reported outcome measures patient satisfaction quality of life
slow-slower progress of calcification with vitamin k2

Conditions: Aortic Valve Stenosis; Aortic Valve Calcification; Mitral Annular Calcification; Mitral Valve Calcification; Mitral Valve Stenosis

Summary: a randomized 12-month trial will include two groups of 100 individuals aged over 50 years, with asymptomatic mild to moderate aortic valve stenosis (ava \> 1 cm2, vmax \ 4 m/s

for the purposes of this study, all individuals will be subjected to the same quantitative and qualitative tests, before and after the daily administration of 300mcg k2 vitamin/placebo for a period of one year.clinical examination,extensive blood laboratory tests,direct measurement of dephosphorylated-uncarboxylated mgp(dp-ucmgp), echocardiogram and ecs,carotid ultrasound,ophthalmologic exam,further imaging methods with msct calcium score(agatston score) will take place.correlations with their medical and pharmacological therapy history. before and after the administration of vk2/placebo, the following measurements will take place i)quantitative and percentile rate determination of aortic valve, mitral valve and ascending aorta calcification via msct calcium score without contrast. ii)echocardiogram and calcification evaluation via echocardiographic calcium score (ecs), iii)determination of changes in carotid intima-media thickness (cimt) and carotid stenosis iv)standard ophthalmologic examination v)direct measurement of dephosphorylated-uncarboxylated mgp(dp-ucmgp) vi)correlation with blood biomarkers

Eligibility criteria:
inclusion criteria: * asymptomatic av stenosis with ava\>1 cm2 \& vmax\<4m/s exclusion criteria: * avk,statins,msct the last 6 months,prosthetic valves, ava\ 4m/s
the prognostic significance of fibrosis detection in cardiomyopathy

Conditions: Cardiomyopathy; Coronary Artery Disease

Summary: the presence of scar within heart muscle can act as a substrate for abnormal rhythm problems and lead to the developement of heart failure clinical significance correlation with biomarkers and genetic markers

patients will undergo cardiovascular magnetic resonance (cmr) to include measurement of left ventricular volumes, ejection fraction, detection of inflammation (via stir sequences) where appropriate, early gadolinium enhancement, late gadolinium enhancement, first pass perfusion using pharmacological stress imaging (contraindications to include comorbidities that do not permit pharmacological stress agents e.g. severe asthma, severe or symptomatic aortic stenosis)

Eligibility criteria:
inclusion criteria: * presence of an ischaemic or non-ischaemic cardiomyopathic process * no contraindication to contrast enhanced cmr * gfr \>30 exclusion criteria: * esrf * contraindication to cm r
the effects of dairy products on energy balance

Conditions: Obesity

Summary: the aim of the study is to investigate the long time effects of high and low intake of dairy products on fecal fat excretion, weight loss, blood pressure, lipid profile, lipid oxidation and appetite regulation in moderately overweight men and women over 24 weeks.


Eligibility criteria:
inclusion criteria: * men and women, * medium overweight (body mass index 28-36 kg/m2), * 18-60 years old, * low habitual calcium intake (\<800 mg/d) exclusion criteria: * milk allergy, infection diseases and diabetes, * intake of dietary supplements, * smoking, * pregnancy and/or breast feeding, * any medications known to affect the outcome measurements, * weigh reducing diet, * gastrointestinal diseases, * participation in other intervention studies

Keywords: obesity metabolic syndrome fecal fat excretion fecal calcium weight loss appetite regulation intestinal micro flora lipid profile energy balance
ketamine use in electroconvulsive therapy

Conditions: Depression

Summary: the purpose of this study is to determine whether combination of ketamine plus electroconvulsive therapy improves depressive symptoms decreasing cognitive side effects.

this study will compare the clinical response to brief pulse ect with infusion of ketamine 0.5 mg/kg versus brief pulse electroconvulsive therapy with infusion of placebo (saline) in major depression. we also will compare levels of cognitive impairment among these groups, compare levels of quality of life among these groups, compare levels of bdnf among these groups. we also will study if levels of 25-hydroxyvitamin d are associated with cognitive impairment in subjects undergoing ect.

Eligibility criteria:
inclusion criteria - patients with unipolar and bipolar depression from the psychiatric unit of hospital de clinicas de porto alegre (diagnosis will be established by the structured clinical interview for dsm-iv axis i) exclusion criteria: * patients with dementia * history of addiction / abuse of psychoactive drugs * other psychiatric diagnoses * refusal to follow the study.
prevention of cardiovascular diseases caused by complex treatment of patients with primary operated breast cancer

Conditions: Women With Breast Cancer

Summary: to develop a method of medical prevention of cardiovascular diseases caused by cardiotoxicity against the background of complex treatment of patients with primary resectable breast cancer to reduce the risk of cardiovascular complications

purpose of the study: to develop a method of medical prevention of cardiovascular diseases caused by cardiotoxicity against the background of complex treatment of patients with primary resectable breast cancer to reduce the risk of cardiovascular complications

Eligibility criteria:
inclusion criteria: * women with breast cancer, with a morphologically confirmed diagnosis before the appointment of anticancer therapy. exclusion criteria: * presence of other oncological diseases
sleep disorder manage in emotional freedom techniques vs sleep hygiene education group therapy

Conditions: Sleep Disorder; Sleep Disorder in Elderly; Sleep Disorder, Mental Health; Sleep Disorders, Physical Health; Sleep Disorder; Insomnia Type; Sleep Hygiene

Summary: sleep disorders are common among elderly persons, with deleterious effects on their physical and mental health. many approaches are used to manage such disorders. aim of the study: to compare the emotional freedom techniques-insomnia (eft-i) and sleep hygiene education (she) group therapy as two treatments for insomnia in a geriatric population when delivered, and their effects on sleep quality, depression, and life satisfaction.

background: sleep disorders are common among elderly persons, with deleterious effects on their physical and mental health. many approaches are used to manage such disorders. aim of the study: to compare the emotional freedom techniques-insomnia (eft-i) and sleep hygiene education (she) group therapy as two treatments for insomnia in a geriatric population when delivered, and their effects on sleep quality, depression, and life satisfaction. participants and methods: this open-label randomized controlled trial study was conducted at elabbasia mental hospital and osana family wellness elderly nursing home at maadi, cairo. it included 60 elderly patients suffering insomnia sleep problem randomized into two equal groups: one group received a sleep hygiene education (she) intervention, the other had a form of emotional freedom techniques (eft) adapted for use with insomnia (eft-i). a self-administered questionnaire with tools for sleep quality (pittsburgh sleep quality index \[psqi\]), depression, and life satisfaction was used to collect data. the fieldwork was from january to march 2021.

Eligibility criteria:
inclusion criteria: * patients suffering insomnia sleep problem * age equal or more than 60 years exclusion criteria: * those having major physical or psychiatric ailments or being on medication affecting their sleep were excluded * these involved those history of epilepsy, seizures, or dementia, current alcohol or substance abuse/dependence (must have \>90 days of sobriety), night shift workers, as well as those unable to complete the study questionnaires and psychological tests.

Keywords: emotional freedom techniques sleep hygiene education geriatric sleep disorders elderly
neuropsychological impairment and quality of life in neurofibromatosis type 1

Conditions: Neurofibromatosis Type 1

Summary: the main objective of the study is to investigate the determinants of the quality of life in children and adults with neurofibromatosis type 1 (nf1) and more particularly the specific impact of neuropsychological deficits. in fact, cognitive impairment is currently considered as one of the most pervasive features of this genetic disorder but its relationship with the worsening of quality of life found in this population has not been directly investigated to date. secondary objectives of this study are (i) to compare neuropsychological and quality of life measures between patients and healthy controls matched by age, gender and education level, (ii) to contrast neuropsychological deficits incidence between patients and controls, and (iii) to differentiate nf1 children's self versus hetero-assessment of quality of life. the main hypothesis of this study is that the neuropsychological impairment classically identified in this clinical population will be associated to the quality of life's worsening both in children and adults.

the study cohort will consist of 150 patients with nf1 (100 adults and 50 children) recruited from the neurofibromatosis clinic at the university hospital in nantes and créteil (france). a sample of 150 healthy controls (100 adults and 50 children) will also be recruited from sport and leisure clubs to serve as a normally developing control group. the protocol assessment includes a standard and thorough neuropsychological examination specific to children and adults, to investigate the different aspects of cognitive domains: language, visuoperceptive and visuomotor abilities, memory, attention, executive function and intelligence skills. quality of life is measured by a questionnaire specifically adapted to children and adults. other factors linked to the nf1 disease (familial or sporadic form, severity and visibility) and to demographic characteristics (sex, age, education level) will be taken into account to study their respective impact on quality of life, as compared with neuropsychological measures.

Eligibility criteria:
inclusion criteria for patients : * nf1 diagnosis following national institutes of health criteria (1988) * age: 8-12 years for children, 18-59 years for adults * signed informed written consent (parent and patient for children, patient for adults) * french speaking * resident in france inclusion criteria for healthy controls: * absence of nf1 diagnosis, learning disabilities, intellectual precocity * age: 8-12 years for children, 18-59 years for adults * signed informed written consent (parent and healthy control for children, healthy control for adults) * french speaking * resident in france exclusion criteria: * uncorrectable hearing of visual impairment * history of psychiatric illness * neuropsychological investigation in the last 6 months * insufficient language usage * any other known history of central nervous system pathology or neuropathological complications of nf1

Keywords: quality of life neuropsychological disorders neurofibromatosis type 1
a study to assess the safety, tolerability, pharmacokinetics and pharmacodynamic activity of intravitreal lka651 in patients with macular edema

Conditions: Macular Edema; Diabetic Macular Edema; Neovascular Age-related Macular Degeneration; Retinal Vein Occlusions

Summary: to evaluate the safety and tolerability of lka651 in patients with macular edema from diabetic macular edema (dme), neovascular age-related macular degeneration (amd), or retinal vein occlusions (rvo)


Eligibility criteria:
inclusion criteria: -patients with macular edema with center involvement in at least one eye, including those with focal or diffuse dme, neovascular amd, or rvo the etdrs letter score in the study eye must be 60 letters or worse (approximate snellen equivalent of 20/63) vital signs as specified within the protocol exclusion criteria: -proliferative diabetic retinopathy in the study eye, with the exception of tufts of neovascularization less than one disc area with no vitreous hemorrhage patient, with type 1 or type 2 diabetes who have a hemoglobin a1c \> or = 12% at screening other ocular conditions as specified in the protocol systemic conditions as specified in the protocol

Keywords: macular edema diabetic macular edema (dme) neovascular age-related macular degeneration(amd) retinal vein occlusions (rvo)
artificial intelligence system for assessment of tumor risk and diagnosis and treatment

Conditions: Artificial Intelligence; Deep Learning; Lung Cancer; Lung; Node; Stomach Cancer; Colon Cancer; Cancer Risk; Cancer Screening; Cancer, Treatment-Related

Summary: to improve the accuracy of risk prediction, screening and treatment outcome of cancer, we aim to establish a medical database that includes standardized and structured clinical diagnosis and treatment information, image features, pathological features, and multi-omics information and to develop a multi-modal data fusion-based technology system using artificial intelligence technology based on database.

the main aims are as follows: 1. to establish a data platform for multi-modal information of common tumors (lung cancer/pulmonary nodules, stomach and colorectal cancers) : electronic medical records (including routine clinical detection, treatment, outcome), pathological image data, medical imaging (ct, mri, ultrasound, nuclear medicine, etc.), multiple omics data (genome, transcriptome, and metabolome, proteomics) omics data, etiology and carcinogenic exposure information. 2. we will make use of artificial intelligence technology to create the multi-modal medical big data cross-analysis technology and the above disease individualized accurate diagnosis and curative effect prediction models. in order to solve the three key problems of multi-modal data fusion mining, such as unbalanced, small sample size, and poor interpretability, we will establish an artificial intelligence recognition algorithm for image images and pathological images, and use image processing and deep learning technologies to mine multi-level depth visual features of image data and pathological data. in addition, we will use bioinformatics analysis algorithms to conduct molecular network mining and functional analysis of molecular markers at the level of multiple omics technologies (pathologic, genomic, transcriptome, metabolome, proteome, etc.).

Eligibility criteria:
inclusion criteria: 1. participants with the suspected of lung cancer/node, or stomach cancer/lesion, or colorectal cancer/leision 2. participants that have signed informed consent. 3. participants with detailed electronic medical records, image records, pathological records, multi-omics information, and other important clinical diagnostic information. 4. healthy participants with no clinical diagnosis of lung cancer/node, or stomach cancer/lesion, or colorectal cancer/leision. exclusion criteria: 1. participants with primary clinical and pathological data missing. 2. participants lost to follow-up. 3. participants with too poor medical image quality to perform segment and mark roi accurately
a prospective, open-ended, multi-center study of schizophrenia patients switching to zolodine

Conditions: Schizophrenia

Summary: through self-controlled studies on metabolic syndrome related indicators, efficacy and other adverse reactions in patients with schizophrenia who developed metabolic syndrome after treatment with other antipsychotics, switched to zoladine capsules (ziprasidone hydrochloride capsules). to evaluate the clinical application value of switching to zolodine for schizophrenia patients with metabolic syndrome, and to explore the drug selection strategy for long-term treatment of schizophrenia patients.


Eligibility criteria:
inclusion criteria: * meet the dsm-iv diagnostic criteria for schizophrenia, patients aged 18-40 years old have been treated with other antipsychotics for more than 8 weeks (inclusive) before being included, meet the diagnostic criteria for metabolic syndrome (idf, 2005), and have not reached diabetes , patients with diagnostic criteria for hypertension. exclusion criteria: * female patients who are pregnant or breastfeeding; * serious and unstable physical diseases, including: cardiovascular, respiratory, liver, kidney, gastrointestinal, nerve, endocrine, immune, blood system, narrow-angle glaucoma, history of seizures; * patients with refractory schizophrenia; * those who meet the dsm-iv standards for dementia or substance dependence (except tobacco); * patients with a history of contraindications to ziprasidone or intolerance of ziprasidone; * patients who use long-acting antipsychotic injections or oral medications; * patients who have recently experienced prolonged qt interval, acute myocardial infarction, and decompensated heart failure; * patients have recently taken drugs that can prolong the qt interval, such as dofetilide, sotalol, quinidine, other class ia and iii antiarrhythmic drugs, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadone, dolastron methanesulfonate acid, probucol or tacrolimus; * at the same time taking other drugs that can cause obesity, such as oral contraceptives; * patients who have met metabolic syndrome before diagnosis and treatment of schizophrenia.
online mindfulness-based tic reduction (phase two)

Conditions: Tourette Syndrome; Persistent Tic Disorder

Summary: tourette syndrome (ts) and persistent tic disorder (ptd) are chronic and potentially disabling neurobiological conditions. although a range of pharmacological and psychosocial treatments exists, a significant number of individuals either do not respond to the current treatments or find them unacceptable. thus, it is essential that researchers continue to develop and test novel treatment approaches. in this randomized controlled trial the investigators will compare two different online group-based interventions for tics: a mindfulness-based program (mindfulness-based intervention for tics (mbit), and a psychoeducational and supportive therapy program (tic information and coping strategies (tics)). the purpose of this study is to determine which intervention is more helpful for adults with a tic disorder.


Eligibility criteria:
inclusion criteria: 1. be 18 years of age or older, 2. possess a primary diagnosis of tourette syndrome or persistent tic disorder, 3. be fluent in english 4. reside in the united states, 5. either not be taking any tic suppressant medication or other psychotropic medication or be at a stable dose for 8 weeks prior to the baseline assessment and throughout the study exclusion criteria: 1. be receiving concurrent psychotherapy for the duration of the study 2. have prior extensive experience with mindfulness and/or meditation and 3. have another medical or psychological condition that would prevent the individual from fully engaging in the study or require a higher level of care (e.g., suicidality).

Keywords: tourette syndrome tic disorder online adults mindfulness therapy
two different dosages of irinotecan combined with cisplatin scheme in extensive disease-small cell lung cancer

Conditions: Small Cell Lung Carcinoma

Summary: as the gene polymorphism of uridine diphosphate glucuronosyl transferase 1a1(ugt1a1)is related to the side effect of diarrhea induced by irinotecan. ugt1a1 gene \*28 (6/6 and 6/7) and \*6 (g/g and g/a) is related to low probability of diarrhea and ugt1a1 gene \*28 (7/7) and \*6 (a/a)is related to high probability of diarrhea. the purpose of this study is to find out the efficacy and side effect between two different dosages of irinotecan combined with cisplatin scheme in extensive disease-small cell lung cancer with ugt1a1 gene \*28 (6/6 and 6/7)and \*6 (g/g and g/a), based on the hypothesis that the ugt1a1 gene \*28 (7/7) and \*6 (a/a)is few in the chinese population and increasing the dose of irinotecan can improve the efficacy without increasing the side effect in the patients with ugt1a1 gene \*28 (6/6 and 6/7)\*6 (g/g and g/a).


Eligibility criteria:
inclusion criteria: * histologic or cytologic diagnosis of small-cell lung cancer * extensive-stage disease, defined as disease extending beyond one hemithorax involving contralateral mediastinal, hilar or supraclavicular lymph nodes, and/or pleural effusion. * males or females between 18 to 75 years * no prior chemotherapy, if the surgery or radiotherapy has been administered, the interval is at least above four weeks. * performance status of 0-2 on the ecog criteria. expected survival is above three months. * at least one unidimensional measurable lesion meeting response evaluation criteria in solid tumors (recist. 2000). * patient compliance that allow adequate follow-up. informed consent from patient or patient's relative. * adequate hematologic (neutrophil count \>= 1,500/ul, platelets \>= 100,000/ul), hepatic (transaminase =\< upper normal limit(unl)x2.5, bilirubin level =\< unl x 1.5), and renal (creatinine =\< unl) function * the gene type of ugt1a1 \*28 is 6/6 and 6/7. * if female: childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of an approved contraceptive method (intrauterine device \[iud\], birth control pills, or barrier device) during and for 3 months after trial. if male, use of an approved contraceptive method during the study and 3 months afterwards. females with childbearing potential must have a urine negative hcg test within 7 days prior to the study enrollment. * no concomitant prescriptions including cyclosporin a, valproic acid, phenobarbital, phenytoin, ketoconazole. exclusion criteria: * non small cell lung cancer and carcinoid * medically uncontrolled severe diarrhea in recent three weeks. * inability to comply with protocol or study procedures. * medically uncontrolled serious heart, lung, neurological, psychological, metabolic disease * second primary malignancy that is clinically detectable at the time of consideration for study enrollment. * pregnant or breast-feeding. * enrollment in other study within 30 days * brain metastasis with symptoms

Keywords: irinotecan; cisplatin; small-cell lung cancer; ugt1a1